Esthesioneuroblastoma medical therapy: Difference between revisions
Simrat Sarai (talk | contribs) No edit summary |
Simrat Sarai (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
===Radiation therapy=== | ===Radiation therapy=== | ||
*In a number of series, radiation therapy alone has been used for the initial treatment of patients with olfactory neuroblastoma, but results have generally been less satisfactory than when radiation therapy (RT) is used in combination with surgery | *In a number of series, radiation therapy alone has been used for the initial treatment of patients with olfactory neuroblastoma, but results have generally been less satisfactory than when radiation therapy (RT) is used in combination with surgery | ||
*Standard techniques include 3-field technnique and a external megavoltage beam; an anterior port is combined with wedged lateral fields to provide a homogeneous dose distribution | *Standard techniques include 3-field technnique and a external megavoltage beam; an anterior port is combined with wedged lateral fields to provide a homogeneous dose distribution. | ||
*The dose of radiotherapy varies from 5500-6500cGy. The majority of patients receive less than 6000 cGy. These doses are close to or exceed the maximum radiation dose recommended for sensitive structures such as the optic chiasma, optic nerve, brainstem, retina, and lens. Therefore, these patients are susceptible to cataract formation and glaucoma. | *The dose of radiotherapy varies from 5500-6500cGy. The majority of patients receive less than 6000 cGy. These doses are close to or exceed the maximum radiation dose recommended for sensitive structures such as the optic chiasma, optic nerve, brainstem, retina, and lens. Therefore, these patients are susceptible to cataract formation and glaucoma. | ||
*A possible role of | *A possible role of intensity-modulated radiotherapy, proton beam radiotherapy, and stereotactic radiation has been suggested. Several studies have reported that intensity-modulated radiotherapy can provide good tumor control with low rates of radiation-induced toxicity, in both adults and children. There are case reports which describe the use of CT-guided interstitial high-dose-rate brachytherapy.<ref name="pmid12173330">{{cite journal| author=Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, Adams J et al.| title=Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. | journal=Cancer | year= 2002 | volume= 94 | issue= 10 | pages= 2623-34 | pmid=12173330 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12173330 }} </ref><ref name="pmid19240832">{{cite journal| author=Nichols AC, Chan AW, Curry WT, Barker FG, Deschler DG, Lin DT| title=Esthesioneuroblastoma: the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. | journal=Skull Base | year= 2008 | volume= 18 | issue= 5 | pages= 327-37 | pmid=19240832 | doi=10.1055/s-2008-1076098 | pmc=PMC2637063 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19240832 }} </ref><ref name="pmid18755554">{{cite journal| author=Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W| title=Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. | journal=Int J Radiat Oncol Biol Phys | year= 2009 | volume= 73 | issue= 2 | pages= 424-32 | pmid=18755554 | doi=10.1016/j.ijrobp.2008.04.037 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18755554 }} </ref><ref name="pmid19775449">{{cite journal| author=Sterzing F, Stoiber EM, Nill S, Bauer H, Huber P, Debus J et al.| title=Intensity modulated radiotherapy (IMRT) in the treatment of children and adolescents--a single institution's experience and a review of the literature. | journal=Radiat Oncol | year= 2009 | volume= 4 | issue= | pages= 37 | pmid=19775449 | doi=10.1186/1748-717X-4-37 | pmc=PMC2760561 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19775449 }} </ref><ref name="pmid18641524">{{cite journal| author=Tselis N, Heyd R, Baghi M, Zamboglou N| title=Interstitial high-dose-rate-brachytherapy in advanced esthesioneuroblastoma. | journal=Laryngoscope | year= 2008 | volume= 118 | issue= 11 | pages= 2006-10 | pmid=18641524 | doi=10.1097/MLG.0b013e3181801d05 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18641524 }} </ref> | ||
*Proton beam therapy may be especially important in children with developing soft tissue, bone, and neurological structures. Proton beam therapy is also being studied as a way to intensify dose and thus improve tumor control particularly in patients with unresectable disease or positive margins. However, there was greater neurological toxicity in patients receiving charged particle therapy compared with those receiving photon therapy.<ref name="pmid25820437">{{cite journal| author=Lucas JT, Ladra MM, MacDonald SM, Busse PM, Friedmann AM, Ebb DH et al.| title=Proton therapy for pediatric and adolescent esthesioneuroblastoma. | journal=Pediatr Blood Cancer | year= 2015 | volume= 62 | issue= 9 | pages= 1523-8 | pmid=25820437 | doi=10.1002/pbc.25494 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25820437 }} </ref> | *Proton beam therapy may be especially important in children with developing soft tissue, bone, and neurological structures. Proton beam therapy is also being studied as a way to intensify dose and thus improve tumor control particularly in patients with unresectable disease or positive margins. However, there was greater neurological toxicity in patients receiving charged particle therapy compared with those receiving photon therapy.<ref name="pmid25820437">{{cite journal| author=Lucas JT, Ladra MM, MacDonald SM, Busse PM, Friedmann AM, Ebb DH et al.| title=Proton therapy for pediatric and adolescent esthesioneuroblastoma. | journal=Pediatr Blood Cancer | year= 2015 | volume= 62 | issue= 9 | pages= 1523-8 | pmid=25820437 | doi=10.1002/pbc.25494 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25820437 }} </ref> | ||
Revision as of 18:40, 28 January 2016
|
Esthesioneuroblastoma Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Esthesioneuroblastoma medical therapy On the Web | |
|
American Roentgen Ray Society Images of Esthesioneuroblastoma medical therapy | |
|
Risk calculators and risk factors for Esthesioneuroblastoma medical therapy | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Medical Therapy
Surgery, radiation therapy (RT), and/or chemotherapy have all been used in the treatment of primary olfactory neuroblastomas.[1]. Observational studies have indicated that combining surgery and radiotherapy RT has resulted in prolonged disease-free and overall survival compared with either surgery or radiotherapy RT alone.
Surgery
Surgical resection of esthesioneuroblastoma originally used a transfacial approach. However, various multiple observational studies have found that a combined craniofacial approach improved the ability to achieve an en bloc resection and resulted in better local control of disease and improved survival compared with a transfacial approach.[2][3][1][4]
Radiation therapy
- In a number of series, radiation therapy alone has been used for the initial treatment of patients with olfactory neuroblastoma, but results have generally been less satisfactory than when radiation therapy (RT) is used in combination with surgery
- Standard techniques include 3-field technnique and a external megavoltage beam; an anterior port is combined with wedged lateral fields to provide a homogeneous dose distribution.
- The dose of radiotherapy varies from 5500-6500cGy. The majority of patients receive less than 6000 cGy. These doses are close to or exceed the maximum radiation dose recommended for sensitive structures such as the optic chiasma, optic nerve, brainstem, retina, and lens. Therefore, these patients are susceptible to cataract formation and glaucoma.
- A possible role of intensity-modulated radiotherapy, proton beam radiotherapy, and stereotactic radiation has been suggested. Several studies have reported that intensity-modulated radiotherapy can provide good tumor control with low rates of radiation-induced toxicity, in both adults and children. There are case reports which describe the use of CT-guided interstitial high-dose-rate brachytherapy.[5][1][6][7][8]
- Proton beam therapy may be especially important in children with developing soft tissue, bone, and neurological structures. Proton beam therapy is also being studied as a way to intensify dose and thus improve tumor control particularly in patients with unresectable disease or positive margins. However, there was greater neurological toxicity in patients receiving charged particle therapy compared with those receiving photon therapy.[9]
Surgery plus radiation therapy
A combined otolaryngologic and neurosurgical anterior craniofacial resection followed by postoperative radiotherapy is the most widely used approach for patients with localized olfactory neuroblastoma [3,4,6,23,38,52,53]. A minimum dose of at least 54 Gy in 30 treatments over six weeks is recommended [54,55].
Adjuvant Chemotherapy
The role of chemotherapy, either before or after RT or surgery, is unclear. Numerous studies have used various chemotherapy regimens in an effort to improve outcomes [57-61]. However, it is unclear whether this actually improves results compared with a combined craniofacial resection and RT. In one study of 11 children, 10 received chemotherapy prior to local therapy with a five-year overall survival in the group of 91 percent [62].
Systemic disease
The rarity of olfactory neuroblastomas, combined with the favorable prognosis following aggressive local regional therapy, has resulted in only very limited experience for patients with disseminated disease. Cytotoxic chemotherapy appears to have activity in some patients, and newer molecularly targeted approaches may become an option as the biology of olfactory neuroblastomas is better understood.
Cytotoxic chemotherapy — A variety of chemotherapy agents have been evaluated in small series. These reports have included a mixture of patients with disseminated disease and with locoregional disease where chemotherapy was used alone or in combination with surgery and/or RT.
Cisplatin-based combination regimens (particularly cisplatin and etoposide) have often been chosen, primarily because of their activity in patients with head and neck squamous cell cancer or related neuroendocrine type tumors [5,64-73]. Non-platinum combinations, such as irinotecan plus docetaxel or doxorubicin, ifosfamide, and vincristine, may also be active [72,73]. Responses in patients with disseminated disease have generally been of short duration.
References
- ↑ 1.0 1.1 1.2 Nichols AC, Chan AW, Curry WT, Barker FG, Deschler DG, Lin DT (2008). "Esthesioneuroblastoma: the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy". Skull Base. 18 (5): 327–37. doi:10.1055/s-2008-1076098. PMC 2637063. PMID 19240832.
- ↑ Dulguerov P, Calcaterra T (1992). "Esthesioneuroblastoma: the UCLA experience 1970-1990". Laryngoscope. 102 (8): 843–9. PMID 1495347.
- ↑ Dulguerov P, Allal AS, Calcaterra TC (2001). "Esthesioneuroblastoma: a meta-analysis and review". Lancet Oncol. 2 (11): 683–90. doi:10.1016/S1470-2045(01)00558-7. PMID 11902539.
- ↑ Levine PA, McLean WC, Cantrell RW (1986). "Esthesioneuroblastoma: the University of Virginia experience 1960-1985". Laryngoscope. 96 (7): 742–6. PMID 3724324.
- ↑ Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, Adams J; et al. (2002). "Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy". Cancer. 94 (10): 2623–34. PMID 12173330.
- ↑ Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W (2009). "Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update". Int J Radiat Oncol Biol Phys. 73 (2): 424–32. doi:10.1016/j.ijrobp.2008.04.037. PMID 18755554.
- ↑ Sterzing F, Stoiber EM, Nill S, Bauer H, Huber P, Debus J; et al. (2009). "Intensity modulated radiotherapy (IMRT) in the treatment of children and adolescents--a single institution's experience and a review of the literature". Radiat Oncol. 4: 37. doi:10.1186/1748-717X-4-37. PMC 2760561. PMID 19775449.
- ↑ Tselis N, Heyd R, Baghi M, Zamboglou N (2008). "Interstitial high-dose-rate-brachytherapy in advanced esthesioneuroblastoma". Laryngoscope. 118 (11): 2006–10. doi:10.1097/MLG.0b013e3181801d05. PMID 18641524.
- ↑ Lucas JT, Ladra MM, MacDonald SM, Busse PM, Friedmann AM, Ebb DH; et al. (2015). "Proton therapy for pediatric and adolescent esthesioneuroblastoma". Pediatr Blood Cancer. 62 (9): 1523–8. doi:10.1002/pbc.25494. PMID 25820437.